INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...

A post-hoc analysis from OTEMTO ® 1&2 indicates that Spiolto ® Respimat ® provides significant quality of life improvements over Spiriva ® Respimat ® (tiotropium) or placebo, right from the initial ...

Spiolto ® Respimat ® more than doubles lung function * improvement over Spiriva ® in patients who had no prior maintenance therapy 2,3 INGELHEIM, Germany -- (BUSINESS WIRE) -- Reduction in ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiolto Respimat contains the active ingredients tiotropium (as ...

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A posthoc analysis from OTEMTO® 1&2 indicates that ...

OTEMTO ® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto ® Respimat ® right from the initial stage when patients first need maintenance therapy * Head-to-head ENERGITO ® ...

GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s ...

Further data from the 1,600 patient OTEMTO® trials show Spiolto® Respimat® provides: clinically meaningful improvements in breathlessness compared to placebo (measured by a 1.62 point improvement in ...

The FINANCIAL — Boehringer Ingelheim on July 2 announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries ...

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO ® 1&2 indicates that ...

Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto ® Respimat ...

OTEMTO trials show Spiolto Respimat provides clinically meaningful >4 point reduction in SGRQ score compared to placebo i The results underline the benefit Spiolto Respimat can bring to the daily life ...